This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Li, G. Articles by Wei, Y.-q. Search for Related Content PubMed PubMed Citation Articles by Li, G. Articles by Wei, Y.-q.

Improved Therapeutic Effectiveness by Combining Recombinant CXC Chemokine Ligand 10 with Cisplatin in Solid Tumors

Authors' Affiliations: ¹ State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Chengdu, Sichuan, The People's Republic of China; and ² Cancer Center, Three Gorges Central Hospital of Chongqing, Chongqing, The People's Republic of China

Requests for reprints: Yu-quan Wei, State Key Laboratory of Biotherapy and Cancer Center, West China Hospital, West China Medical School, Sichuan University, Guo Xue Xiang No. 37, Chengdu, Sichuan, 610041, The People's Republic of China. Fax: 86-28-85250731; E-mail: yuquawei{at}vip.sina.com or yuquawei{at}hotmail.com.

Purpose: CXC chemokine ligand 10 (CXCL10) is a potent inhibitor of angiogenesis. We wonder whether the combination of CXCL10 with cisplatin would improve the therapeutic antitumor efficacy.

Experiment Design: We evaluated the antitumor activity of the combination therapy in the immunocompetent C57BL/6 and BALB/c mice bearing LL/2 Lewis lung cancer and CT26 colon adenocarcinoma, respectively. Mice were treated with either CXCL10 s.c. at 25 µg per kg per day once daily for 30 days, cisplatin cycled twice (5 mg/kg i.p. on days 14 and 21 after the initiation of CXCL10), or both agents together. Tumor volume and survival time were observed. Antiangiogenesis of CXCL10 in vivo were determined by alginate capsule models and CD31 immunohistochemistry. Histologic analysis and assessment of apoptotic cells were also conducted in tumor tissues.

Results: CXCL10 + cisplatin reduced tumor growth in LL/2 and CT26 tumor model, respectively, more effectively, although cisplatin or CXCL10 individually resulted in suppression of tumor growth and improved survival time of tumor-bearing mice. CXCL10 successfully inhibited angiogenesis as assessed by alginate model and CD31 (P < 0.05). Histologic analysis of tumors exhibited that CXCL10 in combination with cisplatin led to the increased rate of apoptosis, tumor necrosis, and elevated lymphocyte infiltration.

Conclusions: Our data suggest that the combination of CXCL10, a well-tolerated angiogenesis inhibitor, with cisplatin can enhance the antitumor activity. The present findings may be of importance to the further exploration of the potential application of this combined approach in the treatment of lung and colon carcinoma.

Key Words: IFN- inducible protein 10 • Antiangiogenesis • Chemotherapy • Immunotherapy

This article has been cited by other articles:

				T. Hosaka, H. Kimura, T. Heishi, Y. Suzuki, H. Miyashita, H. Ohta, H. Sonoda, T. Moriya, S. Suzuki, T. Kondo, et al. Vasohibin-1 Expression in Endothelium of Tumor Blood Vessels Regulates Angiogenesis Am. J. Pathol., July 1, 2009; 175(1): 430 - 439. [Abstract] [Full Text] [PDF]

				P. A. Bunn Jr. and N. Thatcher Introduction Oncologist, January 1, 2008; 13(suppl_1): 1 - 4. [Abstract] [Full Text] [PDF]

				Y.-s. Wang, G.-q. Wang, Y.-j. Wen, L. Wang, X.-c. Chen, P. Chen, B. Kan, J. Li, C. Huang, Y. Lu, et al. Immunity against Tumor Angiogenesis Induced by a Fusion Vaccine with Murine {beta}-Defensin 2 and mFlk-1 Clin. Cancer Res., November 15, 2007; 13(22): 6779 - 6787. [Abstract] [Full Text] [PDF]

				A. Zipin-Roitman, T. Meshel, O. Sagi-Assif, B. Shalmon, C. Avivi, R. M. Pfeffer, I. P. Witz, and A. Ben-Baruch CXCL10 Promotes Invasion-Related Properties in Human Colorectal Carcinoma Cells Cancer Res., April 1, 2007; 67(7): 3396 - 3405. [Abstract] [Full Text] [PDF]